BioAdaptives, Inc. (BDPT)
OTCMKTS · Delayed Price · Currency is USD
0.0825
+0.0175 (26.85%)
May 14, 2025, 4:00 PM EDT

BioAdaptives Company Description

BioAdaptives, Inc. investigates, markets, and distributes natural plant, algal, and mushroom-based products and medical devices for humans and animals.

It offers nutraceutical products, such as dietary supplements. The company offers PluriPain, a fast acting long lasting natural pain relief formulation; PrimiLungs; MindNMemory, a nootropic formulation that enhances memory, focus, mental clarity, and endurance; PrimiSleep, a natural soporific that aids relaxation and sleep quality; Cell Rejuven that increases energy and mobility and resistance to stress, activates primitive cells, improves wound healing, and promotes hair and nail growth; and ProteinNMore, which builds lean bulk muscle, and promotes muscle contractility and strength, as well as helps in improving blood flow.

It also provides SleepEZ for use as an aid to relaxation; Lung Flute, a medical device, and PrimiLungs, a formulation of nutraceuticals promoting overall health and wellness through support of pulmonary immune systems in its Lung Armor packaging; and animal products, including Equine All-in-One and Equine All-In-One Plus formulation for trainers, horse owners, and boarding stables, as well as a Canine All-in-One that is marketed directly to consumers.

The company was formerly known as APEX 8 Inc. and changed its name to BioAdaptives, Inc. in September 2013.

BioAdaptives, Inc. was incorporated in 2013 and is based in Las Vegas, Nevada.

BioAdaptives, Inc.
Country United States
Founded 2013
Industry Packaged Foods
Sector Consumer Staples
Employees 1
CEO James Keener

Contact Details

Address:
2620 Regatta Drive
Las Vegas, Delaware 89128
United States
Phone 702 659 8829
Website shopbioadaptives.com

Stock Details

Ticker Symbol BDPT
Exchange OTCMKTS
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
ISIN Number US09072U1079
SIC Code 2834

Key Executives

Name Position
James E. Keener Chief Executive Officer and Chairman